CCM
PTGX icon

Consonance Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Consonance Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,446,874
Closed -$155M – 24
2021
Q2 		$155M Buy
3,446,874
+737,165
+27% +$24.3M 18.62% 1
2021
Q1 		$70.2M Sell
2,709,709
-20,000
-0.7% -$506K 7.48% 4
2020
Q4 		$55M Buy
2,729,709
+360,000
+15% +$7.75M 5.14% 9
2020
Q3 		$46.3M Buy
+2,369,709
New +$44.5M 5.64% 7

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Consonance Capital Management's PTGX Position: Q3 2021 in Review

Consonance Capital Management sold out of Protagonist Therapeutics (PTGX) in Q3 2021, closing a stake of 3,446,874 shares — an estimated $155M sold.

Consonance Capital Management first reported a position in PTGX in Q3 2020 and held it in 4 quarters. The position peaked at $155M in Q2 2021. 132 funds tracked by Wall St. Rank hold PTGX as of Q3 2021.

  • Consonance Capital Management reported no remaining Protagonist Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Consonance Capital Management sold 3,446,874 Protagonist Therapeutics shares in Q3 2021, an estimated $155M.
  • Consonance Capital Management first reported a position in Protagonist Therapeutics in Q3 2020 and held it in 4 quarters.
  • Consonance Capital Management's Protagonist Therapeutics position peaked at $155M in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2021.

Based on Consonance Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.